Home FDA Accepts For Review ELIQUIS (apixaban) Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE), And For The Reduction In The Risk Of Recurrent DVT And PE
 

Keywords :   


FDA Accepts For Review ELIQUIS (apixaban) Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE), And For The Reduction In The Risk Of Recurrent DVT And PE

2013-12-30 05:21:47| drugdiscoveryonline News Articles

Bristol-Myers Squibb Company and Pfizer Inc. recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Supplemental New Drug Application (sNDA) for ELIQUIS (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE

Tags: the of and review

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
25.11 SGY-PM910ZW
25.11Pioneer DJ DDJ-SP1 DJ
25.11Dr.STONE
25.11
25.1146 dvd
25.11 SONY 4 CUH-1100A
25.11 COMPLETE DVD-BOX6
25.11DAHON /(330mm8°)
More »